Faron Pharmaceuticals Oyj | Mutual Funds
Mutual Funds that own Faron Pharmaceuticals Oyj
City Financial Absolute Equity Fund
1,105,530
3.56%
0
0.5%
09/29/2017
Rhenman & Partners Fund - Healthcare Equity L/S
759,265
2.45%
165,865
0.08%
12/31/2017
Marlborough UK Micro Cap Growth Fund
718,176
2.31%
11,112
0.07%
03/29/2018
Ilmarinen Mutual Pension Insurance
636,721
2.04%
0
0%
12/31/2017
Marlborough Special Situations Fund
537,127
1.73%
6,179
0.04%
03/29/2018
Amati VCT 2 Plc
122,993
0.4%
2,139
0.2%
01/31/2018
Hargreave Hale AIM VCT 2 Plc
94,640
0.31%
94,640
0.2%
02/28/2017
Hargreave Hale AIM VCT 1 Plc
72,508
0.23%
-20,171
0.11%
09/30/2017
Octopus AIM VCT 2 Plc
64,181
0.21%
64,181
0.09%
05/31/2017
Aviva Investors - European Equity Fund
54,516
0.18%
0
0.04%
06/30/2018
| Address |
Joukahaisenkatu 6
Turku FP 20520
Finland
|
|
Employees
|
- |
| Website |
http://www.faron.com |
| Updated |
07/08/2019 |
| Faron Pharmaceuticals Oy engages in the provision of biopharmaceutical development. The company focuses on novel treatments for medical conditions such as acute organ traumas, cancer immunotherapy and vascular damage. It operates through the Traumakine and Clevegen brands for acute respiratory distress syndrome, and for pre-clinical anti-Clever-1 antibody respectively. |
